KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Assets (2016 - 2025)

Vertex Pharmaceuticals has reported Assets over the past 17 years, most recently at $25.6 billion for Q4 2025.

  • Quarterly results put Assets at $25.6 billion for Q4 2025, up 13.8% from a year ago — trailing twelve months through Dec 2025 was $25.6 billion (up 13.8% YoY), and the annual figure for FY2025 was $25.6 billion, up 13.8%.
  • Assets for Q4 2025 was $25.6 billion at Vertex Pharmaceuticals, up from $24.9 billion in the prior quarter.
  • Over the last five years, Assets for VRTX hit a ceiling of $25.6 billion in Q4 2025 and a floor of $12.1 billion in Q1 2021.
  • Median Assets over the past 5 years was $20.2 billion (2023), compared with a mean of $19.3 billion.
  • Biggest five-year swings in Assets: surged 36.23% in 2021 and later fell 4.34% in 2025.
  • Vertex Pharmaceuticals' Assets stood at $13.4 billion in 2021, then skyrocketed by 35.13% to $18.2 billion in 2022, then grew by 25.23% to $22.7 billion in 2023, then dropped by 0.87% to $22.5 billion in 2024, then rose by 13.8% to $25.6 billion in 2025.
  • The last three reported values for Assets were $25.6 billion (Q4 2025), $24.9 billion (Q3 2025), and $24.0 billion (Q2 2025) per Business Quant data.